Clinical trials: GFAP
Neurofilament Light Chain, Glial Fibrillary Acidic Protein
Analysis of NfL and GFAP in Different Dietary Patterns
This observational study aims to investigate the impact of different dietary patterns on brain tissue biomarkers in healthy young adults by measuring blood levels of NfL and GFAP.
- Conditions
- Neurofilament Light Chain, Glial Fibrillary Acidic Protein, GFAP, Vegan Diet
- Trial name
- NCT07312994
- Where
- Austria
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Salzburger Landeskliniken
NMDAR Autoimmune Encephalitis, LGI1 Antibody Associated Encephalitis
Medium-term Effects of Treatments in Autoimmune Encephalitis
Autoimmune encephalitides are severe neurological disorders requiring urgent treatment, even though there is no standard guideline by lack of empirical evidence.
- Conditions
- NMDAR Autoimmune Encephalitis, LGI1 Antibody Associated Encephalitis, CASPR2-Antibody, IgLON5
- Trial name
- META (NCT07133113)
- Testing
- We aim to assess the clinical response to the treatment initiation protocols most commonly used in autoimmune encephalitis (first-line, first-line with rituximab, dual immunosuppression).
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Hospices Civils de Lyon
Fatigue in Multiple Sclerosis, Multiple Sclerosis
Fatigue in Multiple Sclerosis and Its Relationship to Inflammatory and Neurodegenerative Markers of the Disease
The study is focused on several independent quantifiable biomarkers (sNfL, sGFAP, mitochondrial activity, genetics and fatigue tests) to obtain more detailed information about MS and its progression.
- Conditions
- Fatigue in Multiple Sclerosis, Multiple Sclerosis, Neurofilaments Light Chains, GFAP
- Trial name
- MITOFATIGUE (NCT07025122)
- Where
- Slovakia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University Hospital, Martin
Cognitive Dysfunction, Alzheimer Disease
Association of Transcranial Alternating Current Stimulation with Digital Cognitive Training for Cognitive Remediation in Older Adults
BACKGROUND Cognitive decline in older adults, especially those who develop Mild Cognitive Impairment and Alzheimer's Disease, currently has limited options of pharmacological treatments, with modest efficacy.
- Conditions
- Cognitive Dysfunction, Alzheimer Disease, Mild Cognitive Impairment, Cognitive Decline
- Trial name
- NCT06733714
- Testing
- Transcranial Alternating Current Stimulation, Digital Cognitive Training
- Where
- Brazil
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Universidade Federal do Rio de Janeiro
Neurological Diseases or Conditions, Neurological Diseases Associated to Anti GFAP Antibodies
Neuropathy and Anti-GFAP Antibodies
Anti-Glial Fibrillary Acidic Protein (GFAP) are antibodies associated to inflammatory diseases of the central nervous system. The GFAP protein is highly expressed by astrocytes explaining these syndromes, but GFAP is also…
- Trial name
- Neuro-GFAP (NCT05742087)
- Testing
- Clinical examination, electroneuromyography (ENMG)
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Hospices Civils de Lyon
Euthyroid Sick Syndromes in Traumatic Brain Injury Patient and GFAP Level
Euthyroid Sick Syndrome (ESS) Effect on Traumatic Brain Injury Patients and Its Relation With GFAP Level
Euthyroid sick syndrome (ESS) effects on patients suffering from traumatic brain injury (TBI) have received little attention. Moreover, there is limited evidence that serum levels of thyroid-related hormones might influence…
- Trial name
- ESS (NCT04806672)
- Volunteers
- 50 people
- Sponsor
- Minia University
Autoimmune GFAP Astrocytopathy
GFAP Auto-immunity : a French Cohort Study
Glial fibrillary acidic protein (GFAP)-Immunoglobulin G (IgG) have recently been described as a biomarker of a novel inflammatory central nervous system (CNS) disorder, termed autoimmune GFAP astrocytopathy.
- Trial name
- GFAP (NCT04463550)
- Testing
- Description and analysis
- Where
- France
- Volunteers
- 38 people
- Sponsor
- Hospices Civils de Lyon